Jonathan Dyer, MD
Dermatology · Columbia, MONPI 1376591073
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,750 of the $2,050 with a category attached, or 85.4%. Pfizer accounts for 85.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $1,750 and has fallen 97.1% since, to $51 in 2025. That places this record below the midpoint for dermatology clinicians in MO, where the typical reported total is $3,173.
Across 12 payments — averaging $170.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- AbbVie$155
- Krystal Biotech Inc$63
- Arcutis Biotherapeutics, Inc.$36
- Regeneron Healthcare Solutions, Inc.$30
- UCB, Inc.$15
Across 57 payments — averaging $1942.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$110K
- Amicus Therapeutics, Inc.$262
What the payments were for
- Consulting fees$1,75085%
- Food & beverage$30015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $1,750 |
| AbbVie | 5 | $155 |
| Krystal Biotech Inc | 3 | $63 |
| Arcutis Biotherapeutics, Inc. | 1 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$1,750
How this compares
$2,050 in reported general payments places this provider in the 35th percentile of 263 dermatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 26 | $398,606 |
| Humira(Cf) PenAdalimumab | 25 | $262,713 |
| Taltz SyringeIxekizumab | 12 | $102,073 |
| Dupixent SyringeDupilumab | 14 | $53,522 |
| Dupixent PenDupilumab | 12 | $45,441 |
| XolairOmalizumab | 12 | $32,704 |
| Triamcinolone Acetonide | 51 | $922 |
| Hydroxychloroquine Sulfate | 15 | $886 |
| Clobetasol Propionate | 28 | $705 |
| Spironolactone | 21 | $522 |
| Doxycycline Monohydrate | 14 | $357 |
| Doxycycline Hyclate | 19 | $280 |
| Prednisone | 14 | $201 |
| Ketoconazole | 24 | $148 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Columbia
- Kaitlin SchiavoColumbia$16K
- Kimberly CayceColumbia$10K
- Justin WelchColumbia$10K
- Brian KimSaint Louis$861K
- Elaine SiegfriedSaint Louis$856K
- Craig LeonardiSaint Louis$569K
- Jonathan CleaverKirksville$483K
- Mary GeorgeSaint Louis$400K
- David CleaverKirksville$371K
- Christy RaineyBranson$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.